Back to search
FDAFDA · Food and drugs·Recall number Z-2345-2020

RayStation 8A Service Pack 1, UDI # 07350002010136 - Product Usage: For radiation therapy and medical oncology which can also be used to administer treatments.

Published June 17, 2020 · Recall initiated: May 18, 2020

Summary

FDA records medical device Class II recall Z-2345-2020, published June 17, 2020 and initiated May 18, 2020. Recalling firm: RAYSEARCH LABORATORIES AB; Status: Terminated; Reported quantity: N/A; Lot: UDI # 07350002010136 Build number: 8.0.1.10. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Software error was identified in the Pencil Beam Scanning (PBS) and Line Scanning (LS) dose calculation algorithms that could result in a local underestimation of expected dose.

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
RAYSEARCH LABORATORIES AB
Distributor
US Nationwide distribution including in the states of Florida, Georgia, Utah, Virginia, California, Maryland, Arizona, Texas, Washington DC, Missouri, Massachusetts, Illinois, Oklahoma, New Jersey, Tennessee, and Louisiana.
Lot
UDI # 07350002010136 Build number: 8.0.1.10
Risk classification
Class II
Area (FDA)
device
Country
Sweden

Related recalls

Questions about this recall

Was RayStation 8A Service Pack 1, UDI # 07350002010136 - Product Usage: For radiation therapy and medical oncology which can also be used to administer treatments. recalled?

Yes. FDA published recall Z-2345-2020 on June 17, 2020. Reported hazard: Software error was identified in the Pencil Beam Scanning (PBS) and Line Scanning (LS) dose calculation algorithms that could result in a local underestimation of expected dose.

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail